Thermal Pulsation with or without Dexamethasone Intracanalicular Insert for Meibomian Gland Dysfunction: A Prospective, Masked Trial

References

• Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922–1929. doi:10.1167/iovs.10-6997a
   PubMed Web of Science ®Google Scholar
• Tao T, Tao L. Systematic review and meta-analysis of treating meibomian gland dysfunction with azithromycin. Eye. 2020;34(10):1797–1808. doi:10.1038/s41433-020-0876-2
   PubMed Web of Science ®Google Scholar
• Ko JS, Seo Y, Chae MK, Jang SY, Yoon JS. Effect of topical loteprednol etabonate with lid hygiene on tear cytokines and meibomian gland dysfunction in prosthetic eye wearers. Eye. 2018;32(2):439–445. doi:10.1038/eye.2017.213
   PubMed Web of Science ®Google Scholar
• Lee H, Chung B, Kim KS, Seo KY, Choi BJ, Kim TI. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. Am J Ophthalmol. 2014;158(6):1172–1183 e1. doi:10.1016/j.ajo.2014.08.015
   PubMed Web of Science ®Google Scholar
• Akyol-Salman I, Azizi S, Mumcu UY, Ates O, Baykal O. Comparison of the Efficacy of Topical N-Acetyl-Cysteine and a Topical Steroid-Antibiotic Combination Therapy in the Treatment of Meibomian Gland Dysfunction. J Ocul Pharmacol Ther. 2011;1:43. doi:10.1089/jop.2010.0110
   Web of Science ®Google Scholar
• Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore MA. Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: a Randomized Clinical Trial. Clinical Ophthalmology (Auckland, NZ. 2020;14:405–418. doi:10.2147/OPTH.S234008
   PubMed Web of Science ®Google Scholar
• Finis D, Konig C, Hayajneh J, Borrelli M, Schrader S, Geerling G. Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy. Randomized Controlled Trial. Cornea. 2014;33(12):1265–1270. doi:10.1097/ICO.0000000000000273
   PubMed Web of Science ®Google Scholar
• Greiner JV. Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clin Exp Ophthalmol. 2013;41(6):524–530. doi:10.1111/ceo.12033
   PubMed Web of Science ®Google Scholar
• Greiner JV. A single LipiFlow(R) Thermal Pulsation System treatment improves meibomian gland function and reduces dry eye symptoms for 9 months. Current Eye Research. 2012;37(4):272–278. doi:10.3109/02713683.2011.631721
   PubMed Web of Science ®Google Scholar
• Lane SS, DuBiner HB, Epstein RJ, et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea. 2012;31(4):396–404. doi:10.1097/ICO.0b013e318239aaea
   PubMed Web of Science ®Google Scholar
• Tyson SL, Bafna S, Gira JP, et al. Multicenter randomized Phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019;45(2):204–212. doi:10.1016/j.jcrs.2018.09.023
   PubMed Web of Science ®Google Scholar
• Walters T, Bafna S, Vold S, et al. Efficacy and Safety of Sustained Release Dexamethasone for the Treatment of Ocular Pain and Inflammation after Cataract Surgery: results from Two Phase 3 Studies. J Clin Exp Ophthalmol. 2016;7:1–11.
   Google Scholar
• Lee A, Blair HA. Dexamethasone Intracanalicular Insert: a Review in Treating Post-Surgical Ocular Pain and Inflammation. Drugs. 2020;80(11):1101–1108. doi:10.1007/s40265-020-01344-6
   PubMed Web of Science ®Google Scholar
• Ocular Therapeutix, Inc. Dextenza. Highlights of Prescribing Information. Available from: https://www.dextenza.com/wp-content/uploads/2019/06/NDA-208742-S001-Dextenza-labeling-19Jun19.pdf. Accessed February 21, 2020.
   Google Scholar
• World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Chalmers RL, Begley CG, Caffery B. Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses. Cont Lens Anterior Eye. 2010;33(2):55–60. doi:10.1016/j.clae.2009.12.010
   PubMed Web of Science ®Google Scholar
• Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA. Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology. 1997;104(2):334–342.
   PubMed Web of Science ®Google Scholar
• Greenwood MD, Gorham RA, Boever KR. A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK). Clinical Ophthalmology (Auckland, NZ. 2020;14:2223–2228. doi:10.2147/OPTH.S265311
   PubMed Web of Science ®Google Scholar
• Larsen J, Whitt T, Parker B, Swan R. A Randomized, Controlled, Prospective Study of the Effectiveness and Safety of an Intracanalicular Dexamethasone Ophthalmic Insert (0.4 Mg) for the Treatment of Post-Operative Inflammation in Patients Undergoing Refractive Lens Exchange (RLE). Clinical Ophthalmol. 2021;15:2211–2217. doi:10.2147/OPTH.S311070
   PubMed Web of Science ®Google Scholar
• Suner IJ, Peden MC. Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy. Clinical Ophthalmology (Auckland, NZ. 2021;15:3859–3864. doi:10.2147/OPTH.S330255
   PubMed Web of Science ®Google Scholar
• Park J, Yoo YS, Shin K, et al. Effects of Lipiflow Treatment Prior to Cataract Surgery: a Prospective, Randomized, Controlled Study: lipiflow prior to cataract surgery. Am J Ophthalmol. 2021;1:34. doi:10.1016/j.ajo.2021.04.031
   Web of Science ®Google Scholar
• Chan AYY, Chuang JC, Wong VWY. Evaluation of Meibomian Gland Dysfunction Among Ophthalmic Healthcare Workers. Clinical Ophthalmology (Auckland, NZ. 2021;15:1201–1206. doi:10.2147/OPTH.S299338
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li J, Xue K, et al. Preoperative Management of MGD with Vectored Thermal Pulsation before Cataract Surgery: a Prospective, Controlled Clinical Trial. Semin Ophthalmol. 2021;36(1–2):2–8. doi:10.1080/08820538.2021.1881567
   PubMed Web of Science ®Google Scholar
• Fallah S, Loer CJ. Effects of Vectored Thermal Pulsation on Objective Tear Film Measures. Cornea. 2021;12:76. doi:10.1097/ICO.0000000000002714
   Web of Science ®Google Scholar
• Li B, Fu H, Liu T, Xu M. Comparison of the therapeutic effect of Meibomian Thermal Pulsation LipiFlow(R) on obstructive and hyposecretory meibomian gland dysfunction patients. Int Ophthalmol. 2020;40(12):3469–3479. doi:10.1007/s10792-020-01533-y
   PubMed Web of Science ®Google Scholar
• Hura AS, Epitropoulos AT, Czyz CN, Rosenberg ED. Visible Meibomian Gland Structure Increases After Vectored Thermal Pulsation Treatment in Dry Eye Disease Patients with Meibomian Gland Dysfunction. Clinical Ophthalmol. 2020;14:4287–4296. doi:10.2147/OPTH.S282081
   PubMed Web of Science ®Google Scholar
• Matossian C. Impact of Thermal Pulsation Treatment on Astigmatism Management and Outcomes in Meibomian Gland Dysfunction Patients Undergoing Cataract Surgery. Clinical Ophthalmology (Auckland, NZ. 2020;14:2283–2289. doi:10.2147/OPTH.S263046
   PubMed Web of Science ®Google Scholar
• Tauber J. A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction. Cornea. 2020;39(4):403–407. doi:10.1097/ICO.0000000000002235
   PubMed Web of Science ®Google Scholar
• Hagen KB, Bedi R, Blackie CA, Christenson-Akagi KJ. Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ. 2018;12:161–168. doi:10.2147/OPTH.S150433
   PubMed Web of Science ®Google Scholar
• Godin MR, Stinnett SS, Gupta PK. Outcomes of Thermal Pulsation Treatment for Dry Eye Syndrome in Patients With Sjogren Disease. Cornea. 2018;37(9):1155–1158. doi:10.1097/ICO.0000000000001621
   PubMed Web of Science ®Google Scholar
• Blackie CA, Coleman CA, Nichols KK, et al. A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day. Clinical Ophthalmology (Auckland, NZ. 2018;12:169–183. doi:10.2147/OPTH.S153297
   PubMed Web of Science ®Google Scholar
• Epitropoulos AT, Goslin K, Bedi R, Blackie CA. Meibomian gland dysfunction patients with novel Sjogren’s syndrome biomarkers benefit significantly from a single vectored thermal pulsation procedure: a retrospective analysis. Clinical Ophthalmology (Auckland, NZ. 2017;11:701–706. doi:10.2147/OPTH.S119926
   PubMed Web of Science ®Google Scholar
• Schallhorn CS, Schallhorn JM, Hannan S, Schallhorn SC. Effectiveness of an Eyelid Thermal Pulsation Procedure to Treat Recalcitrant Dry Eye Symptoms After Laser Vision Correction. J Refract Surg. 2017;33(1):30–36. doi:10.3928/1081597X-20161006-05
   PubMed Web of Science ®Google Scholar
• Kim MJ, Stinnett SS, Gupta PK. Effect of thermal pulsation treatment on tear film parameters in dry eye disease patients. Clinical Ophthalmology (Auckland, NZ. 2017;11:883–886. doi:10.2147/OPTH.S136203
   PubMed Web of Science ®Google Scholar
• Gibbons A, Waren D, Yesilirmak N, et al. Ocular Surface Parameters Predicting Patient Satisfaction After a Single Vectored Thermal Pulsation Procedure for Management of Symptomatic Meibomian Gland Dysfunction. Cornea. 2017;36(6):679–683. doi:10.1097/ICO.0000000000001196
   PubMed Web of Science ®Google Scholar
• Zhao Y, Veerappan A, Yeo S, et al. Clinical Trial of Thermal Pulsation (LipiFlow) in Meibomian Gland Dysfunction With Preteatment Meibography. Eye Contact Lens. 2016;42(6):339–346. doi:10.1097/ICL.0000000000000228
   PubMed Web of Science ®Google Scholar
• Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clinical Ophthalmology (Auckland, NZ. 2016;10:1385–1396. doi:10.2147/OPTH.S109663
   PubMedGoogle Scholar
• Greiner JV. Long-Term (3 Year) Effects of a Single Thermal Pulsation System Treatment on Meibomian Gland Function and Dry Eye Symptoms. Eye Contact Lens. 2016;42(2):99–107. doi:10.1097/ICL.0000000000000166
   PubMed Web of Science ®Google Scholar
• Satjawatcharaphong P, Ge S, Lin MC. Clinical Outcomes Associated with Thermal Pulsation System Treatment. Optom Vis Sci. 2015;92(9):e334–41. doi:10.1097/OPX.0000000000000670
   PubMed Web of Science ®Google Scholar
• Blackie CA, Carlson AN, Korb DR. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. Current Opinion in Ophthalmology. 2015;26(4):306–313. doi:10.1097/ICU.0000000000000165
   PubMed Web of Science ®Google Scholar
• Finis D, Hayajneh J, Konig C, Borrelli M, Schrader S, Geerling G. Evaluation of an automated thermodynamic treatment (LipiFlow(R)) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. Randomized Controlled Trial. Ocul Surf. 2014;12(2):146–154. doi:10.1016/j.jtos.2013.12.001
   PubMed Web of Science ®Google Scholar
• Pang SP, Chen YT, Tam KW, Lin IC, Loh EW. Efficacy of Vectored Thermal Pulsation and Warm Compress Treatments in Meibomian Gland Dysfunction: a Meta-Analysis of Randomized Controlled Trials. Cornea. 2019;38(6):690–697. doi:10.1097/ICO.0000000000001907
   PubMed Web of Science ®Google Scholar
• Sabeti S, Kheirkhah A, Yin J, Dana R. Management of meibomian gland dysfunction: a review. Survey of Ophthalmology. 2020;65(2):205–217. doi:10.1016/j.survophthal.2019.08.007
   PubMed Web of Science ®Google Scholar
• Thode AR, Latkany RA. Current and Emerging Therapeutic Strategies for the Treatment of Meibomian Gland Dysfunction (MGD). Drugs. 2015;75(11):1177–1185. doi:10.1007/s40265-015-0432-8
   PubMed Web of Science ®Google Scholar
• Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52(4):2050–2064. doi:10.1167/iovs.10-6997g
   PubMed Web of Science ®Google Scholar
• Gira JP, Sampson R, Silverstein SM, Walters TR, Metzinger JL, Talamo JH. Evaluating the patient experience after implantation of a 0.4 mg sustained release dexamethasone intracanalicular insert (Dextenza): results of a qualitative survey. Patient Preference and Adherence. 2017;11:487–494. doi:10.2147/PPA.S126283
   PubMed Web of Science ®Google Scholar
• Walters T, Endl M, Elmer TR, Levenson J, Majmudar P, Masket S. Sustained-release dexamethasone for the treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2015;41(10):2049–2059. doi:10.1016/j.jcrs.2015.11.005
   PubMed Web of Science ®Google Scholar
• Stephenson PDG. Real-world evaluation of postoperative in-office Dexamethasone intracanalicular insert administration for control of postoperative inflammation following cataract surgery. J Clin Ophthalmol. 2020;4(3):273–278.
   Google Scholar
• Trivedi RH, Wilson ME. A sustained-release intracanalicular dexamethasone insert (Dextenza) for pediatric cataract surgery. J AAPOS. 2021;25(1):43–45. doi:10.1016/j.jaapos.2020.10.001
   PubMed Web of Science ®Google Scholar
• Ibach MJ, Shafer BM, Wallin DD, et al. and Safety of Dextenza 0.4 mg for the Treatment of Postoperative Inflammation and Pain in Patients After Photorefractive Keratectomy: the RESTORE Trial. J Refract Surg. 2021;37(9):590–594. doi:10.3928/1081597X-20210610-05
   PubMed Web of Science ®Google Scholar
• McLaurin EB, Evans D, Repke CS, et al. Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis. Am J Ophthalmol. 2021;229:288–300. doi:10.1016/j.ajo.2021.03.017
   PubMed Web of Science ®Google Scholar
• Kenyon KR, McLaurin E, Silverstein S. Phase 3 Trial Evaluating an Intracanalicular Dexamethasone Insert (0.4 mg) for the Treatment of Patients with Allergic Conjunctivitis. presented at: American Society of Cataract and Refractive Surgery Annual Meeting; May 16, 2020. 2020; Virtual.
   Google Scholar
• Torkildsen G, Abelson MB, Gomes PJ, McLaurin E, Potts SL, Mah FS. Vehicle-Controlled, Phase 2 Clinical Trial of a Sustained-Release Dexamethasone Intracanalicular Insert in a Chronic Allergen Challenge Model. J Ocul Pharmacol Ther. 2017;33(2):79–90. doi:10.1089/jop.2016.0154
   PubMed Web of Science ®Google Scholar
• Blizzard C, Desai A, Driscoll A. Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs. J Ocul Pharmacol Ther. 2016;32(9):595–600. doi:10.1089/jop.2016.0025
   PubMed Web of Science ®Google Scholar
• Driscoll A, Blizzard C. Toxicity and Pharmacokinetics of Sustained-Release Dexamethasone in Beagle Dogs. Adv Ther. 2016;33(1):58–67. doi:10.1007/s12325-015-0280-7
   PubMed Web of Science ®Google Scholar
• Blizzard C, McLaurin EB, Driscoll A, et al. Plasma Pharmacokinetic Parameters of Dexamethasone Following Administration of a Dexamethasone Intracanalicular Insert in Healthy Adults. Clinical Ophthalmology (Auckland, NZ. 2021;15:2055–2061. doi:10.2147/OPTH.S307194
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye. 2021;1:56. doi:10.1038/s41433-021-01668-x
   Web of Science ®Google Scholar